Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of
AP23573 in patients with refractory or recurrent malignancies, including myeloma and
lymphoma.